D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $32.00 price target on the stock.

Highlights,Compass Therapeutics sees increased institutional engagement, with major firms expanding their holdings.,Research firms adjust ratings, reflecting varied perspectives on the company’s market trajectory.,The company advances lead therapeutic can...

Guggenheim analyst Debjit Chattopadhyay initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $19 price target The company has

Research analysts at Guggenheim began coverage on shares of Compass Therapeutics (NASDAQ:CMPX – Get Free Report) in a research note issued on Monday, MarketBeat reports. The firm set a “buy” rating and a $12.